Description: Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Home Page: www.regulusrx.com
4224 Campus Point Court
San Diego,
CA
92121
United States
Phone:
858 202 6300
Officers
| Name | Title |
|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director |
| Ms. Crispina Calsada CPA | Chief Financial Officer |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director |
| Mr. Daniel J. Penksa | VP of Finance & Controller |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1183 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |